Abstract
Background. The efficacy and tolerability of peginterferonα-2a and peginterferonα-2b in chronic hepatitis C (CHC) patients remain controversial.Methods. PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently.Results. The overall sustained virologic response (SVR) rate of the peginterferonα-2a group was significantly higher than that of the peginterferonα-2b group (46.7% versus 42.4%,Pvalue = 0.01). The same tendency was observed for naïve, genotype 1/4, and genotype 2/3 patients. The early virologic response (EVR) and end-of-treatment response (ETR) rates were significantly higher in the peginterferonα-2a group than in the peginterferonα-2b group (56.1% versus 49.8%,P<0.0001; 67.9% versus 56.6%,P<0.00001, resp.). Peginterferonα-2a had a significantly lower discontinuation rate than peginterferonα-2b (27.9% versus 33.9%,P<0.0001) in naïve patients. In both naïve CHC and hepatitis C virus genotype 1 patients, peginterferonα-2a had a higher relapse rate than peginterferonα-2b.Conclusions. Peginterferonα-2a has superior efficacy with higher EVR, ETR, and SVR than peginterferonα-2b for CHC patients, both plus ribavirin. Peginterferonα-2a might obtain a similar or even lower discontinuation rate than peginterferonα-2b. However, peginterferonα-2a had a higher relapse rate than peginterferonα-2b.
Funding Information
  • Shanghai Science and Technology Commission (25382, 20114y020, 10F115)
  • Shanghai Municipal Health Bureau (25382, 20114y020, 10F115)
  • Fundamental Research Funds for the Central Universities (25382, 20114y020, 10F115)

This publication has 34 references indexed in Scilit: